Saw this stock ripping on a Friday afternoon. Took a big position and scaled out the next day to lower cost basis to 106. I traded this stock last year for a great run so I was familiar with what it can do.
Why $IFMK Skyrocketed in February There does not appear to be any direct news from the company. But it seems like that there was some coordination by day traders on social media. $IFMK shares were buoyed — thanks to discussions and speculation on Twitter and Twitter hashtags at the start of the month. iFresh Inc is an Asian/Chinese grocery supermarket chain in...
Symmetrical Triangle breakout. Bullish MACD cross. Likely gap up tomorrow after major news today: Empower Partners with Rexall(R) To Launch Integrated Healthcare Centres Partnership Accelerates Empower's Strategy To Execute National Healthcare Centre Expansion By Bringing Accessible and Progressive Primary Care and Para-Medical Care to Millions of...
Rising triangle has been broken on the upside. Upside is the base of the the of triangle, $10. It may reach ATH, ~$46.
T2 Biosystems T2SARS-CoV-2™ Panel Proves Capable of Detecting the Brazil P.1 Variant of the SARS-CoV-2 Virus Panel is capable of detecting 99.99% of all currently identified SARS-CoV-2 viruses based on sequence alignments and in silico analysis. finance.yahoo.com
#ENLV is in the news last week with regards to Covid-19 treatment. I would be looking at the 18.46 area for a retest, and possible entry if we find support. 100% measured move would take the breakout to 23.81 and ultimately that would be my first target. Id consider this trade still healthy above 15.49 and ultimately any lower than 14.54 i would stop out of a...
OCGN: What do they do: mainly focus on developing eye disease therapy. they stepped into the Covid vaccine play and they have a strong product coming – COVAXIN –get this : vaccine can be at room temperature that is huge! transporting and storing with cooling can triple the costs and Pfizer’s vaccine has to be in cooling conditions and if I am not mistaken –...
Ocugen and Bharat Biotech Announce Execution of Definitive Agreement for the Commercialization of COVAXIN™ in the US Market. Definitive Agreement provides details of the previously announced intent to co-develop COVAXIN™ for the US market. Ocugen and Bharat Biotech to share US commercialization profits. Ocugen to receive initial supply of COVAXIN™ doses from...
Eurobio-Scientific took a really good expansion doing covid tests last year. Graphic talks for itself, enjoy the upstream :)
After an amazing uptrend last year due to COVID tests development, Novacyt consolidates in a symetrical triangle before deciding the newt trend.
Lexaria Bioscience Corp. Announces Uplisting to Nasdaq Capital Market and Pricing of $9.6 Million Upsized Public Offering Lexaria also announced the pricing of an underwritten public offering (the "Offering") of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of...
TYME Granted U.S. Patent Claims Covering Use of TYME-19 to Treat COVID-19 Infections TYME announced that it has received notification that the United States Patent and Trademark Office has granted additional patent claims related to the Company’s metabolomic technology platform. The patent, U.S. Patent No. 10,905,698, is directed to methods for treating...
The long-term trend chart of profitable HELLOFRESH is presented. Its rising is supported by its strong fundamentals. ___ Prompt: New traders should take some time and carefully read the post entitled 'You can't beat the market' that is located in my profile. Disclaimer The author of this text is not an investment advisor. The preceding content is intended to be...
Aeterna Zentaris Announces Evaluation and Potential Development of an Oral Prophylactic Bacterial Vaccine Against COVID-19 Through Exclusive Option Agreement with Julius-Maximilians-University Wuerzburg - Company secures next step to continue to build-out pipeline of assets. - University researchers developed a proprietary and orally active bacterial vaccine...
A little-known biotech is trying its hand at developing a coronavirus vaccine. Can it succeed? over the past year, Vaxart stock has soared over 1,250% because of its spot in the lucrative coronavirus vaccine race. Its stock performance even outpaced those of biotechs that have already brought their coronavirus vaccines to market, such as Moderna and...
Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial First to Demonstrate Clinical Efficacy Against COVID-19 and Both UK and South Africa Variants Strong efficacy in Phase 3 UK trial with over 50% of cases attributable to the now-predominant UK variant and the remainder attributable to COVID-19 virus Clinical efficacy demonstrated in Phase...
S/R flip seems really probable here I went long looking for at least $2.30
After making a major price correction throughout December, MRNA started in 2021 a new upward movement that is ongoing and leading it to new highs. Note that 1) the correction was made with a very large volume, which means that the shares left the portfolios of the many and passed into those of the few 2) the RSI has not yet entered the overbought area and...